The estimated Net Worth of Christopher U Missling is at least $10.2 Million dollars as of 28 March 2024. Christopher Missling owns over 73,380 units of Anavex Life Sciences stock worth over $6,790,017 and over the last 21 years he sold AVXL stock worth over $76,200. In addition, he makes $3,380,040 as President, Chief Executive Officer, Secretary, and Director at Anavex Life Sciences.
Christopher has made over 48 trades of the Anavex Life Sciences stock since 2003, according to the Form 4 filled with the SEC. Most recently he exercised 73,380 units of AVXL stock worth $96,862 on 28 March 2024.
The largest trade he's ever made was exercising 500,000 units of Anavex Life Sciences stock on 28 June 2023 worth over $800,000. On average, Christopher trades about 12,555 units every 122 days since 2003. As of 28 March 2024 he still owns at least 1,323,590 units of Anavex Life Sciences stock.
You can see the complete history of Christopher Missling stock trades at the bottom of the page.
Dr. Christopher U. Missling Ph.D. serves as President, Chief Executive Officer, Secretary, Director of the Company. He has over 20 years of healthcare industry experience in the big pharmaceutical, biotech and investment banking industries. Most recently, from March, 2007 until 2013, Dr. Missling served as the head of healthcare investment banking at Brimberg & Co. in New York, New York. Also, Dr. Missling served as the Chief Financial Officer of Curis, Inc. (NASDAQ:CRIS) and ImmunoGen, Inc. (NASDAQ:IMGN). Dr. Missling earned his MS and PhD from the University of Munich and an MBA from Northwestern University Kellogg School of Management and WHU Otto Beisheim School of Management. He has served as Chairman of the Board of Directors of the Company since July 5, 2013.
As the President, Chief Executive Officer, Secretary, and Director of Anavex Life Sciences, the total compensation of Christopher Missling at Anavex Life Sciences is $3,380,040. There are no executives at Anavex Life Sciences getting paid more.
Christopher Missling is 54, he's been the President, Chief Executive Officer, Secretary, and Director of Anavex Life Sciences since 2015. There are 2 older and 5 younger executives at Anavex Life Sciences. The oldest executive at Anavex Life Sciences Corporation is Stephan Toutain, 55, who is the Chief Operating Officer.
Christopher's mailing address filed with the SEC is 630 5TH AVENUE, 20TH FLOOR, , NEW YORK, NY, 10111.
Over the last 18 years, insiders at Anavex Life Sciences have traded over $5,238,591 worth of Anavex Life Sciences stock and bought 135,460 units worth $453,776 . The most active insiders traders include Athanasios Skarpelos, Christopher U Missling, and Elliot Favus. On average, Anavex Life Sciences executives and independent directors trade stock every 99 days with the average trade being worth of $335,876. The most recent stock trade was executed by Peter D.O. Donhauser on 14 June 2024, trading 2,835 units of AVXL stock currently worth $10,319.
anavex life sciences corp. is a clinical stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodevelopmental and neurodegenerative diseases. anavex is currently in a phase 2a trial for alzheimer's disease (ad) with lead therapeutic, anavex 2-73, an orally available small molecule targeting protein misfolding and cellular stress through activating the sigma-1 receptor. part a topline data of our ongoing phase 2a trial demonstrate a favorable safety, bioavailability, dose-response curve and tolerability/risk profile. anavex 2-73 is a potential platform drug showing encouraging preclinical data rare neurodevelopmental disease: rett syndrome, as well is in epilepsy and multiple sclerosis (ms). in 2015, the company was awarded a research by the michael j. fox foundation (mjff) to study anavex 2-73 for the treatment of parkinson’s disease. headquartered in new york, anavex is an american publicly traded corporation quoted as avxl.
Anavex Life Sciences executives and other stock owners filed with the SEC include: